Dr. Foreman obtained his MB ChB at the University of Sheffield and completed a fellowship at St. Jude Children’s Research Hospital. He has been at the University of Colorado since 1995, where he founded the Neuro-Oncology Program, now comprising seven dedicated laboratories. He is a tenured Professor and holds the Seebaum Tschetter Chair of Neuro-Oncology. 

Dr. Foreman’s laboratory and clinical research focus on childhood ependymoma. His group was the first to identify the critical role of the immune microenvironment in ependymoma. His work has focused on developing therapies for high-risk Posterior Fossa Group A (PFA) ependymoma with 1q gain and/or 6q loss. More recently, his laboratory demonstrated that the risk of de novo 6q loss increases with each relapse. 

Dr. Foreman has served as Chair of the Children’s Oncology Group (COG) Ependymoma Subcommittee since 1999 and has played a leading role in the development of ependymoma clinical trials. The upcoming COG high-risk ependymoma trial is based on discoveries from his laboratory.